ID SNU-423 AC CVCL_0366 SY SNU423; NCI-SNU-423 DR BTO; BTO_0003187 DR CLO; CLO_0009099 DR EFO; EFO_0002348 DR ArrayExpress; E-MTAB-38 DR ArrayExpress; E-MTAB-783 DR ArrayExpress; E-MTAB-2706 DR ArrayExpress; E-MTAB-2770 DR ArrayExpress; E-MTAB-3610 DR ATCC; CRL-2238 DR BioGRID_ORCS_Cell_line; 813 DR BioSample; SAMN03471849 DR BioSample; SAMN03473132 DR BioSample; SAMN10987943 DR cancercelllines; CVCL_0366 DR Cell_Model_Passport; SIDM01199 DR ChEMBL-Cells; CHEMBL3308367 DR ChEMBL-Targets; CHEMBL1075584 DR Cosmic; 871513 DR Cosmic; 909737 DR Cosmic; 1177681 DR Cosmic; 1995641 DR Cosmic; 2023869 DR Cosmic; 2162532 DR Cosmic; 2321037 DR Cosmic-CLP; 909737 DR DepMap; ACH-000493 DR EGA; EGAS00001000610 DR EGA; EGAS00001000978 DR GDSC; 909737 DR GEO; GSM565923 DR GEO; GSM887626 DR GEO; GSM888711 DR GEO; GSM936781 DR GEO; GSM1670470 DR GEO; GSM2551588 DR IARC_TP53; 6308 DR IGRhCellID; SNU423 DR KCLB; 00423 DR LiGeA; CCLE_063 DR LIMORE; SNU423 DR LINCS_LDP; LCL-1935 DR PharmacoDB; SNU423_1461_2019 DR PRIDE; PXD030304 DR Progenetix; CVCL_0366 DR PubChem_Cell_line; CVCL_0366 DR Wikidata; Q54955197 RX PubMed=7543080; RX PubMed=8824565; RX PubMed=19956504; RX PubMed=20215515; RX PubMed=22460905; RX PubMed=23505090; RX PubMed=23887712; RX PubMed=25485619; RX PubMed=25574106; RX PubMed=25877200; RX PubMed=26589293; RX PubMed=27397505; RX PubMed=28196595; RX PubMed=30894373; RX PubMed=31063779; RX PubMed=31068700; RX PubMed=31378681; RX PubMed=31978347; RX PubMed=35839778; WW Info; LCCL; -; https://lccl.zucmanlab.com/hcc/cellLines/SNU423 WW Info; MCLP; -; https://tcpaportal.org/mclp/ CC Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE). CC Part of: COSMIC cell lines project. CC Part of: Liver Cancer Model Repository (LIMORE). CC Part of: MD Anderson Cell Lines Project. CC Part of: Seoul National University (SNU) cell line collection. CC Population: Korean. CC Doubling time: 72 hours (PubMed=7543080); 36.62 hours (PubMed=31378681). CC HLA typing: A*11:01,33:03; B*15:02,58:01; C*03:02,08:01 (PubMed=26589293). CC Microsatellite instability: Stable (MSS) (Sanger). CC Sequence variation: Mutation; HGNC; HGNC:11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=31068700; PubMed=31378681). CC Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; c.376-2A>G; ClinVar=VCV000186236; Zygosity=Unspecified; Note=Splice acceptor mutation (PubMed=8824565; PubMed=31378681; DepMap=ACH-000493). CC Transformant: NCBI_TaxID; 10407; Hepatitis B virus (HBV). CC Omics: Genomics; DNA methylation analysis. CC Omics: Genomics; Whole exome sequencing. CC Omics: Genomics; Whole genome sequencing. CC Omics: Phenotyping; Drug screening. CC Omics: Proteomics; Expression; Reverse-phase protein array. CC Omics: Proteomics; Quantitative. CC Omics: Transcriptomics; Microarray. CC Omics: Transcriptomics; miRNA profiling; Microarray. CC Omics: Transcriptomics; RNAseq. CC Omics: Variations; SNP array analysis. CC Genome ancestry: African=0%; Native American=0.82%; East Asian, North=62.68%; East Asian, South=36.24%; South Asian=0%; European, North=0%; European, South=0.26% (PubMed=30894373). CC Derived from site: In situ; Liver; UBERON=UBERON_0002107. ST Source(s): ATCC=CRL-2238; Cosmic-CLP=909737; KCLB=00423; PubMed=25877200; PubMed=31378681 ST Amelogenin: X,Y ST CSF1PO: 11,12 (ATCC=CRL-2238; KCLB=00423; PubMed=25877200; PubMed=31378681) ST CSF1PO: 11,12,13 (Cosmic-CLP=909737) ST D13S317: 10,13 ST D16S539: 9 ST D18S51: 12,13 ST D19S433: 14,16.2 ST D21S11: 30 ST D2S1338: 19,24 ST D3S1358: 17 (PubMed=25877200) ST D3S1358: 17,18 (ATCC=CRL-2238; KCLB=00423) ST D5S818: 10 ST D7S820: 12 ST D8S1179: 11,16 ST FGA: 21,24 ST Penta D: 9 ST Penta E: 11,12 ST TH01: 6,9 (ATCC=CRL-2238; Cosmic-CLP=909737) ST TH01: 9 (KCLB=00423; PubMed=25877200; PubMed=31378681) ST TPOX: 8 ST vWA: 15 DI NCIt; C7956; Adult hepatocellular carcinoma DI ORDO; Orphanet_210159; Adult hepatocellular carcinoma OX NCBI_TaxID=9606; ! Homo sapiens (Human) SX Male AG 40Y CA Cancer cell line DT Created: 04-04-12; Last updated: 10-04-25; Version: 44 // RX PubMed=7543080; DOI=10.1002/ijc.2910620308; RA Park J.-G., Lee J.-H., Kang M.-S., Park K.-J., Jeon Y.-M., Lee H.-J., RA Kwon H.-S., Park H.-S., Yeo K.-S., Lee K.-U., Kim S.-T., Chung J.-K., RA Hwang Y.-J., Lee H.-S., Kim C.Y., Lee Y.I., Chen T.-R., Hay R.J., RA Song S.-Y., Kim W.-H., Ki C.-W., Kim Y.-I.; RT "Characterization of cell lines established from human hepatocellular RT carcinoma."; RL Int. J. Cancer 62:276-282(1995). // RX PubMed=8824565; DOI=10.1002/(SICI)1097-0215(19960917)67:6<898::AID-IJC22>3.0.CO;2-X; RA Kang M.-S., Lee H.-J., Lee J.-H., Ku J.-L., Lee K.P., Kelley M.J., RA Won Y.-J., Kim S.-T., Park J.-G.; RT "Mutation of p53 gene in hepatocellular carcinoma cell lines with HBX RT DNA."; RL Int. J. Cancer 67:898-902(1996). // RX PubMed=19956504; DOI=10.4143/crt.2005.37.1.1; PMCID=PMC2785416; RA Ku J.-L., Park J.-G.; RT "Biology of SNU cell lines."; RL Cancer Res. Treat. 37:1-19(2005). // RX PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458; PMCID=PMC2881662; RA Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., RA Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., RA Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., RA Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., RA Haber D.A.; RT "A genome-wide screen for microdeletions reveals disruption of RT polarity complex genes in diverse human cancers."; RL Cancer Res. 70:2158-2164(2010). // RX PubMed=22460905; DOI=10.1038/nature11003; PMCID=PMC3320027; RA Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., RA Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., RA Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., RA Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., RA Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., RA Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., RA Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., RA Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., RA Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., RA Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., RA Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.; RT "The Cancer Cell Line Encyclopedia enables predictive modelling of RT anticancer drug sensitivity."; RL Nature 483:603-607(2012). // RX PubMed=23505090; DOI=10.1002/hep.26402; RA Wang K., Lim H.Y., Shi S., Lee J., Deng S.-B., Xie T., Zhu Z., RA Wang Y.-L., Pocalyko D., Yang W.J., Rejto P.A., Mao M., Park C.-K., RA Xu J.-C.; RT "Genomic landscape of copy number aberrations enables the RT identification of oncogenic drivers in hepatocellular carcinoma."; RL Hepatology 58:706-717(2013). // RX PubMed=23887712; DOI=10.1038/ncomms3218; PMCID=PMC3731665; RA Nault J.-C., Mallet M., Pilati C., Calderaro J., Bioulac-Sage P., RA Laurent C., Laurent A., Cherqui D., Balabaud C., Zucman-Rossi J.; RT "High frequency of telomerase reverse-transcriptase promoter somatic RT mutations in hepatocellular carcinoma and preneoplastic lesions."; RL Nat. Commun. 4:2218.1-2218.7(2013). // RX PubMed=25485619; DOI=10.1038/nbt.3080; RA Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S., RA Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G., RA Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J., RA Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., RA Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., RA Settleman J., Seshagiri S., Zhang Z.-M.; RT "A comprehensive transcriptional portrait of human cancer cell RT lines."; RL Nat. Biotechnol. 33:306-312(2015). // RX PubMed=25574106; DOI=10.3748/wjg.v21.i1.311; PMCID=PMC4284350; RA Cevik D., Yildiz G., Ozturk M.; RT "Common telomerase reverse transcriptase promoter mutations in RT hepatocellular carcinomas from different geographical locations."; RL World J. Gastroenterol. 21:311-317(2015). // RX PubMed=25877200; DOI=10.1038/nature14397; RA Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M., RA Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S., RA Neve R.M.; RT "A resource for cell line authentication, annotation and quality RT control."; RL Nature 520:307-311(2015). // RX PubMed=26589293; DOI=10.1186/s13073-015-0240-5; PMCID=PMC4653878; RA Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P., RA Loewer M., Sahin U., Castle J.C.; RT "TCLP: an online cancer cell line catalogue integrating HLA type, RT predicted neo-epitopes, virus and gene expression."; RL Genome Med. 7:118.1-118.7(2015). // RX PubMed=27397505; DOI=10.1016/j.cell.2016.06.017; PMCID=PMC4967469; RA Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., RA Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., RA Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., RA Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., RA Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., RA Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., RA Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., RA Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.; RT "A landscape of pharmacogenomic interactions in cancer."; RL Cell 166:740-754(2016). // RX PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005; PMCID=PMC5501076; RA Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P., RA Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L., RA Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., RA Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B., RA Liang H.; RT "Characterization of human cancer cell lines by reverse-phase protein RT arrays."; RL Cancer Cell 31:225-239(2017). // RX PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747; PMCID=PMC6445675; RA Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.; RT "An interactive resource to probe genetic diversity and estimated RT ancestry in cancer cell lines."; RL Cancer Res. 79:1263-1273(2019). // RX PubMed=31063779; DOI=10.1053/j.gastro.2019.05.001; RA Caruso S., Calatayud A.-L., Pilet J., La Bella T., Rekik S., RA Imbeaud S., Letouze E., Meunier L., Bayard Q., Rohr-Udilova N., RA Peneau C., Grasl-Kraupp B., de Koning L., Ouine B., Bioulac-Sage P., RA Couchy G., Calderaro J., Nault J.-C., Zucman-Rossi J., Rebouissou S.; RT "Analysis of liver cancer cell lines identifies agents with likely RT efficacy against hepatocellular carcinoma and markers of response."; RL Gastroenterology 157:760-776(2019). // RX PubMed=31068700; DOI=10.1038/s41586-019-1186-3; PMCID=PMC6697103; RA Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., RA McDonald E.R. 3rd, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X., RA Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., RA Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., RA Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., RA Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., RA Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., RA Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., RA Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., RA Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., RA Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., RA Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., RA Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., RA Sellers W.R.; RT "Next-generation characterization of the Cancer Cell Line RT Encyclopedia."; RL Nature 569:503-508(2019). // RX PubMed=31378681; DOI=10.1016/j.ccell.2019.07.001; PMCID=PMC7505724; RA Qiu Z.-X., Li H., Zhang Z.-T., Zhu Z.-F., He S., Wang X.-J., RA Wang P.-C., Qin J.-J., Zhuang L.-P., Wang W., Xie F.-B., Gu Y., RA Zou K.-K., Li C., Li C., Wang C.-H., Cen J., Chen X.-T., Shu Y.-J., RA Zhang Z., Sun L.-L., Min L.-H., Fu Y., Huang X.-W., Lv H., Zhou H., RA Ji Y., Zhang Z.-G., Meng Z.-Q., Shi X.-L., Zhang H.-B., Li Y.-X., RA Hui L.-J.; RT "A pharmacogenomic landscape in human liver cancers."; RL Cancer Cell 36:179-193.e11(2019). // RX PubMed=31978347; DOI=10.1016/j.cell.2019.12.023; PMCID=PMC7339254; RA Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. 3rd, RA Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K., RA Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K., RA Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A., RA Sellers W.R., Gygi S.P.; RT "Quantitative proteomics of the Cancer Cell Line Encyclopedia."; RL Cell 180:387-402.e16(2020). // RX PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010; PMCID=PMC9387775; RA Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., RA Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., RA Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., RA Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., RA Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., RA Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.; RT "Pan-cancer proteomic map of 949 human cell lines."; RL Cancer Cell 40:835-849.e8(2022). //